Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Mark Lebwohl, Richard B. Warren, Howard Sofen, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 5, pp. 668-679
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature
Andreea Roxana Furtunescu, Simona Roxana Georgescu, Mircea Tampa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4681-4681
Open Access | Times Cited: 10
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO‐1, PSO‐4, and LTE trials
Akimichi Morita, Shinichi Imafuku, Yayoi Tada, et al.
The Journal of Dermatology (2025)
Open Access | Times Cited: 1
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
JAMA Dermatology (2024)
Open Access | Times Cited: 6
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses
Oliver FitzGerald, Dafna D. Gladman, Philip J. Mease, et al.
Arthritis & Rheumatology (2024) Vol. 76, Iss. 9, pp. 1397-1407
Open Access | Times Cited: 5
Dual‐Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self‐Locking Microneedles
Ziyi Wang, Ze Qiang Zhao, Yu Sheng, et al.
Advanced Science (2024)
Open Access | Times Cited: 4
Dual inhibition of JAK3 and PD-L1 boosts immune response in triple negative breast cancer
Huali Xiang, Binfeng Tu, Xin Feng, et al.
Anti-Cancer Drugs (2025)
Closed Access
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Joseph F. Merola, Laura K. Ferris, Jeffrey M. Sobell, et al.
Dermatology and Therapy (2025)
Open Access
Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2025)
Open Access
IL-23 blockade in a patient with psoriasis and Toxoplasma gondii reactivation history: Case report and review
Jason Dagher, Julien Ringuet
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
April W. Armstrong, Mark Lebwohl, Richard B. Warren, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Open Access
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
April W. Armstrong, Leon Kircik, Linda Stein Gold, et al.
Dermatology and Therapy (2025)
Open Access
The IL-12/IL-23 Cytokine Family
Maria Alejandra Clavijo-Salomon, Giorgio Trinchieri, Vito Pistoia
Elsevier eBooks (2025)
Closed Access
Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database
Haowen Tan, Xiubi Chen, Xuan Ou, et al.
Research Square (Research Square) (2025)
Closed Access
Advances in genetic–immunological targeted therapies for psoriasis
Zhen Qi, Yirui Wang, Zhuo Li, et al.
Current Opinion in Immunology (2025) Vol. 94, pp. 102559-102559
Closed Access
Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
Y. Xu, X LIU, Linghong Guo, et al.
Clinical Cosmetic and Investigational Dermatology (2025) Vol. Volume 18, pp. 1121-1135
Open Access
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition
Martina Dragotto, Martina D’Onghia, Emanuele Trovato, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3091-3091
Open Access | Times Cited: 3
Tyrosine kinase 2 inhibitors in autoimmune diseases
Chethana Ramakrishna, Alice Mason, Christopher J Edwards
Autoimmunity Reviews (2024), pp. 103649-103649
Closed Access | Times Cited: 3
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Neil J. Korman, Richard B. Warren, Jerry Bagel, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Response to Deucravacitinib in Psoriasis Patients with Prior Biologic Therapy Failures: A Retrospective Study
Katie Lovell, Steven R. Feldman
Journal of the American Academy of Dermatology (2024)
Open Access | Times Cited: 1
Presenting JAK inhibitor safety information to dermatology patients
A. Teixeira, Jessica Q. Duong, Shirley P. Parraga, et al.
JEADV Clinical Practice (2024)
Open Access | Times Cited: 1
Molecular and cellular mechanisms of itch sensation and the anti-itch drug targets
Meng Sun, Ze Chen, Huijuan Ding, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 1
Deucravacitinib: is there still a place or a need for a new oral agent?
Francesca Sampogna, Stefano Piaserico
British Journal of Dermatology (2024) Vol. 190, Iss. 5, pp. 610-611
Closed Access
Pityriasis rosea-like drug eruption secondary to deucravacitinib
Nisal Punchihewa, Senhong Lee, Chin‐Guan Tan, et al.
JAAD Case Reports (2024) Vol. 53, pp. 63-65
Open Access
Page 1 - Next Page

Scroll to top